We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
W. Brian Gibler, MD, FACEP, FACC, FAHA
Natalie Kreitzer, MD, MS
Adrian R. Parry-Jones, FRCP, PhD
David Seiffge, MD
Audience Q&A
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Selecting an AUD Treatment: Naltrexone
Ethan A. Cowan, MD
Edwin A. Salsitz, MD, DFASAM
Case-Based AUD Challenge
Annie Levesque, MD, MSc
Epidemiology of AUD and Patient Stratification
Selecting an AUD Treatment: Disulfiram
Strategies for Referral to AUD Treatment
Assessing a Patient’s Willingness to Accept Treatment for AUD
Selecting an AUD Treatment: Off-Label Agents
How, When, and Why to Conduct Brief AUD Interventions
Improved Strategies for Treating Alcohol Use Disorder (AUD)
Standardized Screening Tools for AUD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education